Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
I-MAB ( (IMAB) ) has issued an announcement.
On October 28, 2025, I-MAB announced the completion of its acquisition of Bridge Health Biotech Co., Ltd. through its subsidiary, I-Mab Biopharma Hong Kong Limited. The transaction, initially disclosed on July 17, 2025, involves an upfront payment of $1.8 million and additional non-contingent payments totaling $1.2 million through 2027, with potential milestone payments of up to $3.875 million. This acquisition grants I-MAB rights to bispecific and multi-specific applications, enhancing its capabilities in developing innovative treatments such as the CLDN18.2 x 4-1BB bispecific antibody, givastomig, thereby strengthening its position in the biopharmaceutical industry.
The most recent analyst rating on (IMAB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
I-MAB is a biopharmaceutical company focused on the discovery and development of novel or highly differentiated biologics, with a particular emphasis on immuno-oncology and autoimmune diseases. The company is known for its innovative approach in creating bispecific and multi-specific antibodies and antibody drug conjugates.
Average Trading Volume: 2,712,157
Technical Sentiment Signal: Buy
Current Market Cap: $334.2M
Learn more about IMAB stock on TipRanks’ Stock Analysis page.